Activation of AMPK by Telmisartan Decreases Basal and PDGF-stimulated VSMC Proliferation via Inhibiting the mTOR/p70S6K Signaling Axis

다국어 초록 (Multilingual Abstract)

Background: Telmisartan, an angiotensin II type 1 receptor blocker (ARB), is widely used to treat hypertension by blocking the renin-angiotensin-aldosterone system. Although abnormal proliferation of vascular smooth muscle cells (VSMCs) is a well-established contributor to the development of various vascular diseases, such as atherosclerosis, the effect of telmisartan on VSMC proliferation and its mechanism of action have not been fully revealed. Herein, we investigated the molecular mechanism whereby telmisartan inhibits rat VSMC proliferation.
Methods: We measured VSMC proliferation by MTT assay, and performed inhibitor studies and western blot analyses using basal and platelet-derived growth factor (PDGF)-stimulated rat VSMCs. To elucidate the role of AMP-activated protein kinase (AMPK), we introduced dominant-negative (dn)-AMPKα1 gene into VSMCs.
Results: Telmisartan decreased VSMC proliferation, which was accompanied by decreased phosphorylations of mammalian target of rapamycin (mTOR) at Ser2448 (p-mTOR-Ser2448 ) and p70 S6 kinase (p70S6K) at Thr389 (p-p70S6K-Thr389 ) in dose- and time-dependent manners. Telmisartan dose- and time-dependently increased phosphorylation of AMPK at Thr172 (p-AMPK-Thr172 ). Co-treatment with compound C, a specific AMPK inhibitor, or ectopic expression of the dn-AMPKα1 gene, significantly reversed telmisartan-inhibited VSMC proliferation, p-mTOR-Ser2448 and p-p70S6K-Thr389 levels. Among the ARBs tested (including losartan and fimasartan), only telmisartan increased p-AMPK-Thr172 and decreased p-mTOR-Ser2448 , p-p70S6K-Thr389 , and VSMC proliferation. Furthermore, GW9662, a specific and irreversible peroxisome proliferator-activated receptor γ (PPARγ) antagonist, did not affect any of the telmisartan-induced changes. Finally, telmisartan also exhibited inhibitory effects on VSMC proliferation by increasing p-AMPK-Thr172 and decreasing p-mTOR-Ser2448 and p-p70S6K-Thr389 in a PDGF-induced in vitro atherosclerosis model.
Conclusion: These results demonstrated that telmisartan-activated AMPK inhibited basal and PDGF-stimulated VSMC proliferation, at least in part, by downregulating the mTOR/p70S6K signaling axis in a PPARγ-independent manner. These observations suggest that telmisartan could be used to treat arterial narrowing diseases such as atherosclerosis and restenosis.

참고문헌 (Reference)

1 Morita M, "mTOR coordinates protein synthesis, mitochondrial activity and proliferation" 14 (14): 473-480, 2015

2 Rivard A, "Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases" 15 (15): 557-571, 2000

3 Dzau VJ, "Vascular proliferation and atherosclerosis : new perspectives and therapeutic strategies" 8 (8): 1249-1256, 2002

4 Zídek V, "Tissue-specific peroxisome proliferator activated receptor gamma expression and metabolic effects of telmisartan" 26 (26): 829-835, 2013

5 Auboeuf D, "Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans : no alteration in adipose tissue of obese and NIDDM patients" 46 (46): 1319-1327, 1997

6 Lacolley P, "The vascular smooth muscle cell in arterial pathology : a cell that can take on multiple roles" 95 (95): 194-204, 2012

7 Markan U, "The place of ARBs in heart failure therapy : is aldosterone suppression the key" 13 : 1753944719868134-, 2019

8 Fuster V, "The pathogenesis of coronary artery disease and the acute coronary syndromes(1)" 326 (326): 242-250, 1992

9 Schwartz SM, "The intima. Soil for atherosclerosis and restenosis" 77 (77): 445-465, 1995

10 Wu H, "The anti-atherosclerotic effect of paeonol against vascular smooth muscle cell proliferation by up-regulation of autophagy via the AMPK/mTOR signaling pathway" 8 : 948-, 2018

11 Papadopoulos N, "The PDGF/PDGFR pathway as a drug target" 62 : 75-88, 2018

12 Destro M, "Telmisartan: just an antihypertensive agent? A literature review" 12 (12): 2719-2735, 2011

13 Yamamoto K, "Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptorgamma activation" 54 (54): 1353-1359, 2009

14 Toba H, "Telmisartan protects against vascular dysfunction with peroxisome proliferator-activated receptor-γ activation in hypertensive 5/6 nephrectomized rats" 92 (92): 265-275, 2013

15 Song KH, "Telmisartan attenuates hyperglycemia-exacerbated VCAM-1 expression and monocytes adhesion in TNFα-stimulated endothelial cells by inhibiting IKKβexpression" 78 : 43-52, 2016

16 Jin Z, "Telmisartan ameliorates vascular endothelial dysfunction in coronary slow flow phenomenon(CSFP)" 36 (36): 18-26, 2018

17 Shawky NM, "Sulforaphane inhibits platelet-derived growth factor-induced vascular smooth muscle cell proliferation by targeting mTOR/p70S6kinase signaling independent of Nrf2 activation" 119 : 251-264, 2017

18 Gomez D, "Smooth muscle cell phenotypic switching in atherosclerosis" 95 (95): 156-164, 2012

19 Miura S, "Review : angiotensin II type 1 receptor blockers : class effects versus molecular effects" 12 (12): 1-7, 2011

20 Hong MK, "Restenosis following coronary angioplasty: current status" 16 (16): 51-55, 2001

21 Li J, "Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway" 18 (18): 2694-2703, 2019

22 Li Z, "Rab1A knockdown represses proliferation and promotes apoptosis in gastric cancer cells by inhibition of mTOR/p70S6K pathway" 685 : 108352-, 2020

23 Diener HC, "Preventing stroke : the PRoFESS, ONTARGET, and TRANSCEND trial programs" 27 (27): S31-S36, 2009

24 Rosen ED, "PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth" 276 (276): 37731-37734, 2001

25 You G, "Metformin activates the AMPK-mTOR pathway by modulating lncRNA TUG1 to induce autophagy and inhibit atherosclerosis" 14 : 457-468, 2020

26 Benson SC, "Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity" 43 (43): 993-1002, 2004

27 Yusuf S, "Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors : a randomised controlled trial" 372 (372): 1174-1183, 2008

28 Kliewer SA, "Differential expression and activation of a family of murine peroxisome proliferator-activated receptors" 91 (91): 7355-7359, 1994

29 Lu QB, "Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFκB/mTOR/P70S6K signaling cascade" 14 : 656-668, 2018

30 Dong X, "CTRP6 inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration" 103 : 844-850, 2018

31 Zhao Y, "Angiotensin II receptor type 1 antagonists modulate vascular smooth muscle cell proliferation and migration via AMPK/mTOR" 143 (143): 1-10, 2019

32 Hwang YJ, "Activation of AMPK/proteasome/MLCK degradation signaling axis by telmisartan inhibits VSMC contractility and vessel contraction" 524 (524): 853-860, 2020

33 Shiota A, "Activation of AMPK-Sirt1 pathway by telmisartan in white adipose tissue : a possible link to anti-metabolic effects" 692 (692): 84-90, 2012

34 Michel MC, "A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists" 65 (65): 809-848, 2013